Early safety study of MTX-101 in healthy adults and adults with type 1 diabetes
Tests MTX-101 in healthy adults and adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
Key facts
- Where
- Fitzroy, Heidelberg, and Melbourne, AustraliaSee the 3 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06324604, who can take part
Where in Australia
- St Vincent's Hospital Melbourne (SVHM)Fitzroy, AustraliaTaking people
- Austin HealthHeidelberg, AustraliaTaking people
- The Royal Melbourne HospitalMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mozart Therapeutics Australia Pty Ltd
- Trial code
- NCT06324604
- Record updated
- 18 May 2026
- Original description
First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.Read full original descriptionShow less
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.
Inclusion: Adults, age ≥ 18 and ≤ 65 years at the time of anticipated dosing (Day 1); Healthy individuals without known current or chronic medical conditions, including no history of any autoimmune diseases, in the opinion of the Investigator; Body mass index (BMI) ≥ 18 kg/m2 and ≤ 35 kg/m2 AND body weight ≥ 55 and ≤ 120 kg; Negative Coronavirus Disease 2019 (COVID-19) test within 24 hours prior to each dose; Persons of child-bearing potential must have a negative pregnancy test and either abstain from sex or use highly effective method(s) of birth control from Day 1 through the duration of the study.
Exclusion: Prior or concurrent malignancies; Receipt of an investigational drug within 28 days or 5 half-lives (whichever is longer) of the investigational drug(s) prior to Day 1; Positive test results for drug screen, including alcohol, at the time of Screening or on Day 1 prior to randomization; Use of tobacco or nicotine-containing products more than the equivalent of 5 cigarettes/week within 30 days prior to (first) dosing; Participants must abstain from nicotine use while inpatient; History of receiving a live vaccine within 1 month of Screening; History of COVID or influenza vaccine within 2 weeks prior to Screening; Any disease or condition that, in the opinion of the Investigator, might significantly compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems; Positive serology for human immunodeficiency virus (HIV) type 1 or 2, hepatitis (Hep) B surface antigen, or Hep C; History of splenectomy; History of recurrent infections of uncertain cause; Clinically significant findings in physical examination (PE), vital signs (blood pressure, heart rate, and body temperature), electrocardiogram (ECG), and safety laboratory parameters at Screening in the opinion of the Investigator; Renal function calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation with estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73 m2 or abnormal level of proteinuria detected by dipstick at the time of Screening; Planning to receive any vaccinations during the study period.